This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Recombinant Alpha 1-antitrypsin
Drug Names(s): rAAT
Description: AAT is a serine protease inhibitor (serpin) which protects tissue from enzymes from inflammatory cells. AAT derived from human plasma is prohibitively expensive, costing up to $100,000 a year. Recombinant AAT is produced by genetically modified organisms following the insertion of the relevant DNA into their genome.
Deal Structure: In March 2000, Baxter and Arriva (at that point, AlphaOne Pharmaceuticals) agreed to co-develop an inhaled, recombinant alpha 1-antitrypsin (rAAT)product. Under the agreement, Baxter received exclusive worldwide marketing and distribution rights for rAAT to treat hereditary emphysema, and an option to develop other pulmonary indications, including asthma, cystic fibrosis andchronic obstructive pulmonary disease.
In May 2002, ZymoGenetics and Arriva signed an agreement that grants Arriva a worldwide license to United States Patent 5,218,091 -- which covers production of rAAT in yeast. As part of the licensing agreement, Arriva will pay to ZymoGenetics an initial license fee along with maintenance fees, milestones and royalty payments. Arriva will be responsible for development and commercialization of rAAT.
In 2005, the license between ZymoGenetics and Arriva was terminated.
Partners: Baxter International Inc.
Recombinant Alpha 1-antitrypsin News
Additional information available to subscribers only: